MMED (NASDAQ:MMED) Now Covered by Bank of America

Equities researchers at Bank of America started coverage on shares of MMED (NASDAQ:MMED) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating and a $27.00 price target on the stock. Bank of America‘s price objective suggests a potential upside of 88.15% from the stock’s previous close.

A number of other research firms have also weighed in on MMED. BTIG Research initiated coverage on shares of MMED in a research note on Tuesday. They issued a “buy” rating and a $25.00 price objective on the stock. Wall Street Zen raised MMED to a “hold” rating in a report on Saturday, March 14th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, MMED has an average rating of “Moderate Buy” and a consensus price target of $22.33.

MMED Price Performance

Shares of NASDAQ:MMED opened at $14.35 on Tuesday. MMED has a twelve month low of $14.10 and a twelve month high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.